Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
Technology appraisal guidance
Reference number: TA1030
Published:
Please note that the evaluation of durvalumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer ID6220, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer.